YZYin Zhou

Yin Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yin Zhou has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Concordance with primary care referral guidelines for breast lumps in Singapore: A retrospective cohort study

    by A.H. Ong, S.C.C. van der Lubbe, A. Szücs, C.Y.J. Goh, D. Young, J.M. Valderas, Y. Zhou

  • Open Access

    Cancer risk in patients with recurrent or persistent symptoms: a systematic review

    by Faye Dannhauser, Natalia Calanzani, Aiman Aslam, Aina Chang, Alka Vimarkant, Malik Majeed, Fiona M. Walter, Yin Zhou

  • Open Access

    Sociodemographic landscape of suspected prostate cancer referrals and diagnoses across North East London

    by Muhammad Haider, Jeffrey J. Leow, James S. A. Green, Chamkhor Dhillon, Angela S. Wong, Yin Zhou, Sara Paparini, Benjamin W. Lamb, Prabhakar Rajan, for the North East London Cancer Alliance Urology Expert Reference Group

    Objectives: The objective of this study is to identify healthcare inequities in referrals and diagnoses of suspected prostate cancer (PCa) in an ethnically diverse and socially deprived large urban region.Methods: Retrospective cohort study of 2‐Week Wait (2WW) suspected PCa patients (n = 12 947) referred to two acute NHS Trusts in North East London (NEL) from February 2019 to August 2023. Sociodemographics, diagnosis and pretreatment staging data were collected from patient records. We examined referral and diagnosis statistics, age at referral, radiological T‐stage at diagnosis, levels of deprivation by ethnicity and the impact of COVID‐19 pandemic lockdowns on proportion of referrals and diagnoses by ethnicity and T‐stage at diagnosis. Uni‐ and multivariable logistic regression was performed to identify predictors of locally advanced (T‐stage ≥T3) disease.Results: Of all referrals, 22% were diagnosed with PCa. There were no statistically significant differences in referrals, diagnoses or T‐stage of PCa by ethnicity during COVID lockdown versus non‐lockdown periods (p > 0.05). Compared to men from any other ethnicity, Black men (from Black British, Black African and Black Caribbean ethnic groups) were diagnosed at a younger age (mean = 65 years), had the highest age‐adjusted PCa incidence rate of 149 per 100 000 person‐years, were from the most deprived backgrounds, and were diagnosed with the highest proportion of localised PCa (74%). Multivariable analysis of a patient subgroup revealed age bands 71–80 years (OR 2.01, 95% CI 1.31–3.07) and >80 (OR 4.27, 95% CI 2.25–8.08) as independent positive predictors of locally advanced PCa, and Black ethnicity as an independent predictor of localised disease (OR 0.66, 95% CI 0.43–1.00). Limitations of this study include the exclusion of PCa cases diagnosed outside the 2WW pathway, as well as missing data on Prostate‐Specific Antigen (PSA) levels, distant radiological staging and histopathological findings.Conclusion: We identify disparities in PCa incidence, stage and age at presentation, as well as socio‐economic deprivation among Black men in NEL. Targeted efforts are needed to mitigate these healthcare inequities.


  • Open Access

    Understanding symptom contribution to sex inequality in bladder and renal cancer stage at diagnosis

    by Yin Zhou, Georgios Lyratzopoulos, Prabhakar Rajan, Fiona M. Walter, Jianhua Wu

    Background: Understanding sex‐specific factors contributing to advanced‐stage diagnosis can guide interventions to reduce sex inequality in patients with urological cancers.Method: We used linked primary care and cancer registry data to examine associations between symptoms and advanced‐stage in 1151 bladder cancer and 440 renal cancer patients diagnosed between January 2012 and December 2015 in England. We performed logistic regression, adjusting for sex, age, deprivation and routes to diagnosis, including interaction terms between symptoms and sex and symptoms and age.Results: Female sex (OR vs. men 1.89 [1.28–2.79]; p = 0.001) and patients presenting with urinary tract infections (OR 2.22 [1.34–3.69]) and abdominal symptoms (OR 2.19 [1.30–3.70]) were associated with increased odds of advanced‐stage bladder cancer (vs. haematuria, p = 0.016 for both). Women with haematuria and men with abdominal symptoms (compared with the opposite sex with the same presenting symptom) were more likely to have advanced‐stage bladder cancer. Neither sex nor symptom associations were observed for renal cancer.Conclusion: Non‐haematuria symptoms are associated with higher risk of advanced‐stage bladder cancer. Greater risk of advanced‐stage bladder cancer in women may reflect biological differences in haematuria onset and sex differences during diagnostic process. Identifying higher risk women with haematuria may reduce sex inequalities in bladder cancer outcomes.


  • Open Access

    Improving early diagnosis of pancreatic cancer in symptomatic patients

    by Amber J Johnston, Shivan Sivakumar, Yin Zhou, Garth Funston, Stephen H Bradley

    Early diagnosis is challenging since pancreatic cancer typically presents with non- specific symptoms that have low positive predictive values (PPVs) for cancer, such as abdominal pain, back pain, and weight loss.4 Consequently, time to referral can be long, as indicated by the relatively high proportion of patients with pancreatic cancer having multiple GP consultations before diagnosis.5 Jaundice is the sole alarm symptom,4 though its reported frequencies range from 12% to 43%, and tends to be a late sign of disease.6 Given the non-specific nature of many presentations, multidisciplinary centres (sometimes known as ‘vague’ or ‘non- specific’ symptom pathways) may improve timely diagnosis of pancreatic cancer. Indeed, an analysis from five such centres showed that, of 241 cancers diagnosed, 25 (10%) were pancreatic cancers.7


  • Open Access

    Pre-diagnostic prescription patterns in bladder and renal cancer: a longitudinal linked data study

    by Garth Funston, Marie Moullet, Luke Mounce, Georgios Lyratzopoulos, Fiona M Walter, Yin Zhou

    Background: Understanding pre-diagnostic prescribing activity could reveal windows during which more timely cancer investigation and detection may occur. Aim: To examine prescription patterns for common urological clinical features prior to renal and bladder cancer diagnoses. Design and setting: A retrospective cohort study was performed using electronic primary care and cancer registry data on patients with bladder and renal cancer, who received their diagnosis between April 2012 and December 2015 in England. Method: Primary care prescriptions up to 2 years pre- diagnosis were analysed for five groups of clinical features (irritative urological symptoms, obstructive symptoms, urinary tract infections [UTIs], genital infections, and atrophic vaginitis). Poisson regressions estimating the inflection point from which the rate of prescriptions increased from baseline were used to identify the start of diagnostic windows during which cancer could be detected. Results: A total of 48 094 prescriptions for 5322 patients were analysed. Inflection points for an increase in UTI prescriptions were identified 9 months pre- diagnosis for renal (95% confidence interval [CI] = 5.3 to 12.7) and bladder (95% CI = 7.4 to 10.6) cancers. For bladder cancer, the change in UTI antibiotic prescription rates occurred 4 months earlier in females (11 months pre- diagnosis, 95% CI = 9.7 to 12.3) than in males (7 months pre-diagnosis, 95% CI = 5.4 to 8.6). For other clinical features, no inflection points were identified and, as such, no diagnostic windows could be defined. Conclusion: Prescription rates for UTIs increased 9 months before bladder and renal cancer diagnoses, indicating that there is potential to expedite diagnosis of these cancers in patients presenting with features of UTI. The greatest opportunity for more timely diagnosis may be in females with bladder cancer, who experienced the earliest increase in UTI prescription rate.


  • Open Access

    Improving the diagnostic process for patients with possible bladder and kidney cancer: a mixed-methods study to identify potential missed diagnostic opportunities

    by Yin Zhou, Hardeep Singh, Willie Hamilton, Stephanie Archer, Sapphire Tan, James Brimicombe, Georgios Lyratzopoulos, Fiona M Walter

    Background: Patients with bladder and kidney cancer may experience diagnostic delays.Aim: To identify patterns of suboptimal care and contributors of potential missed diagnostic opportunities (MDOs).Design and setting: Prospective, mixed-methods study recruiting participants from nine general practices in Eastern England between June 2018 and October 2019.Method: Patients with possible bladder and kidney cancer were identified using eligibility criteria based on National Institute for Health and Care Excellence (NICE) guidelines for suspected cancer. Primary care records were reviewed at recruitment and at 1 year for data on symptoms, tests, referrals, and diagnosis. Referral predictors were examined using logistic regression. Semi-structured interviews were undertaken with 15 patients to explore their experiences of the diagnostic process, and these were analysed thematically.Results: Participants (n= 940) were mostly female (n= 657, 69.9%), with a median age of 71 years (interquartile range 64–77 years). In total, 268 (28.5%) received a referral and 465 (48.5%) had a final diagnosis of urinary tract infection (UTI). There were 33 (3.5%) patients who were diagnosed with cancer, including prostate (n= 17), bladder (n= 7), and upper urothelial tract (n= 1) cancers. Among referred patients, those who had a final diagnosis of UTI had the longest time to referral (median 81.5 days). Only one-third of patients with recurrent UTIs were referred despite meeting NICE referral guidelines. Qualitative findings revealed barriers during the diagnostic process, including inadequate clinical examination, female patients given repeated antibiotics without clinical reviews, and suboptimal communication of test results to patients.Conclusion: Older females with UTIs might be at increased risk of MDOs for cancer. Targeting barriers during the initial diagnostic assessment and follow-up might improve quality of diagnosis.